Cargando…
The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
INTRODUCTION: Clinical evidence comparing chemotherapy and tyrosine kinase inhibitors (TKIs) as second-line therapy for epidermal growth factor receptor (EGFR) wild-type non-small-cell lung cancer (NSCLC) are conflicting. METHODS: We retrospectively reviewed stage IV EGFR wild-type NSCLC patients wh...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079695/ https://www.ncbi.nlm.nih.gov/pubmed/27799795 http://dx.doi.org/10.2147/OTT.S119341 |
_version_ | 1782462585883328512 |
---|---|
author | Xu, Jianlin Ding, Guozheng Zhang, Xueyan Jin, Bo Lou, Yuqing Zhang, Yanwei Wang, Huiming Wu, Dan Han, Baohui |
author_facet | Xu, Jianlin Ding, Guozheng Zhang, Xueyan Jin, Bo Lou, Yuqing Zhang, Yanwei Wang, Huiming Wu, Dan Han, Baohui |
author_sort | Xu, Jianlin |
collection | PubMed |
description | INTRODUCTION: Clinical evidence comparing chemotherapy and tyrosine kinase inhibitors (TKIs) as second-line therapy for epidermal growth factor receptor (EGFR) wild-type non-small-cell lung cancer (NSCLC) are conflicting. METHODS: We retrospectively reviewed stage IV EGFR wild-type NSCLC patients who relapsed on first-line chemotherapy at the Shanghai Chest Hospital to compare the efficacy of TKIs and chemotherapy as second-line therapy among different clinical subgroups. RESULTS: The progression-free survival (PFS) and overall survival for patients receiving chemotherapy as second-line therapy for NSCLC were longer than patients who received TKIs. The hazard ratios (HRs) were 0.40 (P<0.001) and 0.50 (P<0.001), respectively. Subgroup analyses showed that second-line TKI therapy resulted in inferior PFS among smokers (HR =0.24, P<0.001), males (HR =0.33, P<0.001), females (HR =0.54, P=0.004), and patients with adenocarcinoma (HR =0.48, P<0.001) and nonadenocarcinoma histology (HR =0.20, P<0.001). Among never-smokers, the PFS in cohorts receiving second-line chemotherapy or TKIs was not significantly different (HR =0.70, P=0.08). CONCLUSION: These results suggest that EGFR TKI therapy was inferior compared to chemotherapy in EGFR wild-type NSCLC patients who relapsed from first-line chemotherapy; however, among never-smokers, these two treatment strategies were comparable. |
format | Online Article Text |
id | pubmed-5079695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50796952016-10-31 The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China Xu, Jianlin Ding, Guozheng Zhang, Xueyan Jin, Bo Lou, Yuqing Zhang, Yanwei Wang, Huiming Wu, Dan Han, Baohui Onco Targets Ther Original Research INTRODUCTION: Clinical evidence comparing chemotherapy and tyrosine kinase inhibitors (TKIs) as second-line therapy for epidermal growth factor receptor (EGFR) wild-type non-small-cell lung cancer (NSCLC) are conflicting. METHODS: We retrospectively reviewed stage IV EGFR wild-type NSCLC patients who relapsed on first-line chemotherapy at the Shanghai Chest Hospital to compare the efficacy of TKIs and chemotherapy as second-line therapy among different clinical subgroups. RESULTS: The progression-free survival (PFS) and overall survival for patients receiving chemotherapy as second-line therapy for NSCLC were longer than patients who received TKIs. The hazard ratios (HRs) were 0.40 (P<0.001) and 0.50 (P<0.001), respectively. Subgroup analyses showed that second-line TKI therapy resulted in inferior PFS among smokers (HR =0.24, P<0.001), males (HR =0.33, P<0.001), females (HR =0.54, P=0.004), and patients with adenocarcinoma (HR =0.48, P<0.001) and nonadenocarcinoma histology (HR =0.20, P<0.001). Among never-smokers, the PFS in cohorts receiving second-line chemotherapy or TKIs was not significantly different (HR =0.70, P=0.08). CONCLUSION: These results suggest that EGFR TKI therapy was inferior compared to chemotherapy in EGFR wild-type NSCLC patients who relapsed from first-line chemotherapy; however, among never-smokers, these two treatment strategies were comparable. Dove Medical Press 2016-10-20 /pmc/articles/PMC5079695/ /pubmed/27799795 http://dx.doi.org/10.2147/OTT.S119341 Text en © 2016 Xu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Xu, Jianlin Ding, Guozheng Zhang, Xueyan Jin, Bo Lou, Yuqing Zhang, Yanwei Wang, Huiming Wu, Dan Han, Baohui The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China |
title | The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China |
title_full | The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China |
title_fullStr | The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China |
title_full_unstemmed | The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China |
title_short | The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China |
title_sort | egfr tyrosine kinase inhibitors as second-line therapy for egfr wild-type non-small-cell lung cancer: a real-world study in people’s republic of china |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079695/ https://www.ncbi.nlm.nih.gov/pubmed/27799795 http://dx.doi.org/10.2147/OTT.S119341 |
work_keys_str_mv | AT xujianlin theegfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT dingguozheng theegfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT zhangxueyan theegfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT jinbo theegfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT louyuqing theegfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT zhangyanwei theegfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT wanghuiming theegfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT wudan theegfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT hanbaohui theegfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT xujianlin egfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT dingguozheng egfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT zhangxueyan egfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT jinbo egfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT louyuqing egfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT zhangyanwei egfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT wanghuiming egfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT wudan egfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina AT hanbaohui egfrtyrosinekinaseinhibitorsassecondlinetherapyforegfrwildtypenonsmallcelllungcancerarealworldstudyinpeoplesrepublicofchina |